ObsEva

105 articles about ObsEva

• Obseva Announces U.S. FDA Acceptance of New Drug Application for Linzagolix

  11/22/2021

  Obseva SA announced that the New Drug Application for linzagolix for the management of heavy menstrual bleeding associated with uterine fibroids in premenopausal women has been accepted for review by the United States Food and Drug Administration.

• Obseva Announces Appointment of Stephanie Brown to its Board of Directors

  11/22/2021

  ObsEva SA, a biopharmaceutical company developing and commercializing novel therapies to improve women’s reproductive health, announced that Stephanie Brown has been selected to join its Board of Directors and will be proposed for election at the 2022 Annual General Meeting.

• ObsEva Announces Management Change

  10/29/2021

  ObsEva SA, a biopharmaceutical company developing and commercializing novel therapies to improve women’s reproductive health, announced that current Chief Financial Officer David Renas will be stepping down from his position for personal reasons, effective January 5, 2022.

• ObsEva Announces Presentation of Clinical Data on Oral GnRH Antagonist Linzagolix at ASRM 2021 Scientific Congress & Expo

  10/19/2021

  ObsEva SA announced two upcoming poster presentations on linzagolix, an oral GnRH antagonist, at the American Society for Reproductive Medicine 2021 Scientific Congress & Expo, being held October 17-20, 2021.

• ObsEva Announces Relationship with Syneos Health to Commercialize Linzagolix

  10/13/2021

  ObsEva SA, a biopharmaceutical company dedicated to improving women’s reproductive health announced a strategic relationship with Syneos Health®, the only fully integrated biopharmaceutical solutions organization, to commercialize linzagolix.

• ObsEva Announces Submission of New Drug Application to U.S. FDA for Linzagolix for the Treatment of Uterine Fibroids

  9/15/2021

  ObsEva SA, a biopharmaceutical company developing and commercializing novel therapies to improve women’s reproductive health, announced that it has submitted a New Drug Application to the U.S. Food and Drug Administration for linzagolix for the treatment of uterine fibroids.

• ObsEva to Present at the H.C. Wainwright 23rd Annual Global Investment Conference

  9/7/2021

  ObsEva SA announced that Company Management will provide a corporate update and participate in one-on-one investor meetings at the H.C. Wainwright 23rd Annual Global Investment Conference to be held September 13-15, 2021.

• ObsEva Announces Second Quarter 2021 Financial Results and Business Update

  8/5/2021

  ObsEva SA, a biopharmaceutical company developing and commercializing novel therapies to improve women’s reproductive health, reported financial results for the quarter ended June 30, 2021 and provided a business update.

• ObsEva Announces Two Cornerstone Publications Describing Clinical Trials of Nolasiban for Improving Pregnancy and Live Birth Outcomes Following IVF

  8/4/2021

  ObsEva SA announced the publication of two peer-reviewed papers on nolasiban, an oxytocin receptor antagonist in development for improving live birth rates in women undergoing embryo transfer following in-vitro fertilization.

• ObsEva to Present at Upcoming Investor Conferences - Aug 03, 2021

  8/3/2021

  ObsEva SA announced that Company Management will provide a corporate update at the Wedbush PacGrow Healthcare Conference to be held August 10-11, 2021 and the Canaccord Genuity 41st Annual Growth Conference to be held August 10-12, 2021.

• 

  Global Roundup: Takeda and PeptiDream Expand CNS Collaboration

  7/29/2021

  Biopharma and life sciences companies from across the globe provide updates on their pipelines and business operations including Takeda, Origin Therapeutics, ERS Genomics and more.

• Organon and ObsEva Enter Global License Agreement to Develop and Commercialize Ebopiprant (OBE022), an Investigational Agent Being Evaluated as a First-in-Class Treatment for Preterm Labor

  7/27/2021

  Organon, a global women’s health company and ObsEva, a biopharmaceutical company dedicated to improving women’s reproductive health, announced that the companies have entered into an agreement whereby Organon will license the global development, manufacturing and commercial rights to ebopiprant.

• ObsEva to Present Ebopiprant (OBE022) Data at the Society for Reproductive Investigation 68th Annual Meeting

  7/2/2021

  ObsEva SA announced the presentation of clinical data from the PROLONG Phase 2a proof-of-concept study of ebopiprant, an oral prostaglandin F2alpha antagonist, for the treatment of spontaneous preterm labor at the Society for Reproductive Investigation 68th Annual Meeting, being held virtually and in Boston July 6 -9, 2021.

• ObsEva Presents Clinical Data on Open-Label Pilot Study of Yselty® (linzagolix) for the Treatment of Severe Adenomyosis at ESHRE Virtual 37th Annual Meeting

  6/30/2021

  ObsEva SA, a biopharmaceutical company developing and commercializing novel therapies to improve women’s reproductive health, announced clinical data from a pilot study on Yselty® for the treatment of severe adenomyosis was presented at the European Society of Human Reproduction and Embryology Virtual 37th Annual Meeting, being held June 26-July 1, 2021.

• ObsEva To Present Data on Two Clinical Development Programs at ESHRE Virtual 37th Annual Meeting

  6/24/2021

  ObsEva SA announced the presentation of data from two of its clinical development programs at the European Society of Human Reproduction and Embryology Virtual 37th Annual Meeting, being held June 26 - July 1, 2021.

• ObsEva Presents PROLONG Phase 2a Proof-of-Concept Data on Ebopiprant (OBE022) for the Treatment of Spontaneous Preterm Labor at the RCOG Virtual World Congress 2021

  6/10/2021

  ObsEva SA announced the presentation of clinical data from the PROLONG Phase 2a proof-of-concept study of ebopiprant for the treatment of spontaneous preterm labor at the Royal College of Obstetricians and Gynecologists Virtual World Congress 2021.

• ObsEva Announces Oral Presentation at the RCOG Virtual World Congress 2021

  6/2/2021

  Data from PROLONG Phase 2a proof-of-concept study of ebopiprant (OBE022) for spontaneous preterm labor to be discussed in an oral presentation

• ObsEva SA Announces that Shareholders Approved all Board Proposals at its 2021 Annual General Meeting held on May 28, 2021

  5/31/2021

  ObsEva SA, a biopharmaceutical company developing and commercializing novel therapies to improve women’s reproductive health, announced that shareholders approved all Board proposals at its 2021 Annual General Meeting held on May 28, 2021.

• ObsEva Announces Proposed Changes to the Composition of its Board of Directors

  5/25/2021

  ObsEva SA announced that its Board of Directors will propose the election at the 2021 Annual General Meeting of Shareholders to be held on May 28, 2021 of Anne VanLent as member of the Board of Directors for a term of one year expiring at the closing of the 2022 Annual General Meeting of Shareholders.

• ObsEva Announces Final Results from the Phase 3 PRIMROSE Program of Yselty® (linzagolix) for the Treatment of Uterine Fibroids

  5/20/2021

  PRIMROSE 1 76-week results confirmPRIMROSE 2 data showing sustained post-treatment effects and evidence of bone mineral density (BMD) recovery following 52 weeks of treatment